Context Partners Fund’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Context Partners Fund’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$2.82M	Buy	+270,000	New	+$2.85M	0.61%	62

Other funds holding CERE

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SRCM

Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Context Partners Fund's CERE Position: Q3 2020 in Review

Context Partners Fund opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2020: 270,000 shares worth $2.82M. The stake represents 0.61% of the portfolio and ranks #62 among its holdings.

18 funds tracked by Wall St. Rank hold CERE as of Q3 2020.

Context Partners Fund held 270,000 shares of Cerevel Therapeutics Holdings, Inc. Common Stock worth $2.82M as of Q3 2020.
Cerevel Therapeutics Holdings, Inc. Common Stock was a new Context Partners Fund position in Q3 2020.
Cerevel Therapeutics Holdings, Inc. Common Stock made up 0.61% of Context Partners Fund's portfolio in Q3 2020, its #62 holding.
18 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2020.

Based on Context Partners Fund's 13F filing for Q3 2020, filed 16 Nov 2020.